by certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed

Patent Application Attorney Docket No.PC11028A

to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 14th day of July, 2004. Ву Tracy Mycroft (Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: L. Kathryn Durham, et al.

APPLICATION NO.: 10/032,241 Examiner: S. A. Sakelaris

FILING DATE: 12/21/01 Group Art Unit: 1634

TITLE: Methods, Compositions and Kits Relating to

Cardiovascular Disease

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Pursuant to the duty of disclosure set forth in 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. § 1.97 and § 1.98, Applicant(s) hereby bring to the Examiner's attention the enclosed PTO-FB-A820 and the listed documents, copies of which are also enclosed.

The Examiner is requested to consider the cited documents and to indicate such consideration by returning a signed and initialed copy of the PTO-FB-A820 Form with the next communication from the Patent Office. Further, it is requested that the cited documents be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 C.F.R. 1.17(p). The Commissioner is further authorized to charge any additional fees, which may be required under 37 C.F.R. 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

Patent Application Attorney Docket No.PC11028A

Should there be any questions regarding the above or the present application, the Examiner is invited to contact the undersigned at the below-listed number.

Respectfully submitted,

Date: July 14, 2004

Gabriel L. Kleiman

Attorney for Applicant(s)

Reg. No. 40,681

Pfizer Inc.

Patent Department, MS 8260-1611 Eastern Point Road Groton, Connecticut 06340 (860) 715-0041

INFORMATION DISCLOSURE CITATION SERIAL NO. 10/032,241 ATTY. DOCKET NO. PC11028A (Use several sheets if necessary) APPLICANT L. Kathryn Durham et al. **GROUP** FILING DATE 12/21/01 1634 **U.S. PATENT DOCUMENTS** EXAMINER INITIAL FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUBCLASS **FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
									==-					
					/									
											0			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Konno et al., GenBank Accession # BB138415, June 28, 2000	
Birren et al., GenBank Accession # AC020769, March 26, 2000	
The DOE Joint Genome Institute, GenBank Accession #AC010550, Sept 4, 2000	
Yamashita et al., Biochim Biophys Acta, 1529, 257-275, Dec 15, 2000	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE